Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

17.39
-0.5300-2.96%
Volume:1.59M
Turnover:28.62M
Market Cap:1.54B
PE:-4.27
High:18.90
Open:18.16
Low:17.39
Close:17.92
Loading ...

Company Profile

Company Name:
Travere Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
385
Office Location:
3611 Valley Centre Drive,Suite 300,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Directors

Name
Position
Gary A. Lyons
Director and Chairman
Stephen Aselage
President,Chief Executive Officer and Director
Cornelius E. Golding
Director
Jeffrey Meckler
Director
John A. Orwin
Director
John W. Kozarich
Director
Ron Squarer
Director
Roy D. Baynes
Director
Tim Coughlin
Director

Shareholders

Name
Position
Stephen Aselage
President,Chief Executive Officer and Director
Neil F. McFarlane
Chief Operating Officer
Elizabeth E. Reed
Senior Vice President, General Counsel and Corporate Secretary
Laura M. Clague
Senior Vice President and Chief Financial Officer
William E. Rote
Senior Vice President and Head of Research and Development